Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome | SpringerLink
Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria - ScienceDirect
Eculizumab - wikidoc
Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States | PLOS ONE
Eculizumab - wikidoc
Practical Guidance for the use of Eculizumab | TCRM
Differential effects of therapeutic complement inhibitors on serum bactericidal activity against non-groupable meningococcal isolates recovered from patients treated with eculizumab | Haematologica
Treatment and Prevention of Community-Acquired Bacterial Meningitis
Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation - ScienceDirect
Current Opinions on the Clinical Utility of Ravulizumab for the Treatm | TCRM
Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantation–Associated Thrombotic Microangiopathy - Biology of Blood and Marrow Transplantation
Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies - American Journal of Transplantation
Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria - ScienceDirect
Frontiers | Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity
Untitled
INITIAL PRE-INTERVENTION DOSES RECOMMENDED IN PROPHYLAXIS | Download Table
Frontiers | Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT
ULTOMIRIS® (ravulizumab-cwvz) | Adult Data
PNH - Part 2 - PNH Management and Treatment Best Practices – CARE™ Education
Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy | Pediatric Nephrology
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial - The Lancet Haematology
Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease
Practical Guidance for the use of Eculizumab | TCRM
Protocol for the prophylactic use of eculizumab for renal transplant in... | Download Table
Treatment and Prevention of Community-Acquired Bacterial Meningitis
